WO2014076203A1 - Pastille medicamenteuse a base d'ibuprofene sodique dihydrate - Google Patents
Pastille medicamenteuse a base d'ibuprofene sodique dihydrate Download PDFInfo
- Publication number
- WO2014076203A1 WO2014076203A1 PCT/EP2013/073868 EP2013073868W WO2014076203A1 WO 2014076203 A1 WO2014076203 A1 WO 2014076203A1 EP 2013073868 W EP2013073868 W EP 2013073868W WO 2014076203 A1 WO2014076203 A1 WO 2014076203A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ibuprofen
- sodium dihydrate
- tablet
- ibuprofen sodium
- dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to medicinal sucking lozenges of solid consistency for dissolving in the oral cavity comprising at least ibuprofen in the form of ibuprofen sodium dihydrate as the active ingredient.
- Inflammatory and painful conditions of the bucco-pharyngeal sphere are penalizing for patients and it is logical to note that the pharmacopoeia is poor to provide rapid relief, effective, sufficient duration and limiting side effects.
- These oral-pharyngeal affections are of various origin and develop in the anterior part, on the mucous membranes of the floor and walls of the mouth, or on the posterior part, on the pharyngeal mucosa.
- the bucco-pharyngeal sphere is a constant and privileged access route for all irritating germs and substances brought by air and food. This zone is also a place of privileged development of bacterial populations, more or less pathogenic viruses justifying a treatment of the inflammations that they generate.
- inflammations can be more or less important and disabling, ranging from the simple sensation of localized discomfort to the presence of macroscopically visible lesions of the type generated by oral aphtoses. Such inflammations are often devoid of major clinical signs such as fever or ganglionic formations.
- the active ingredient must therefore be metabolized by the whole organism inducing a widespread distribution of the molecule in all organs and tissues. This broad dissemination is useless for the most part because to treat the 2% that represents the bucco-pharyngeal sphere, 100% of the body is treated.
- the first is that a sufficient dose must be given to the patient, taking into account dilution and dispersion in the body, so that the significantly active part that reaches the affected area is sufficiently effective.
- the second problem concerns the latency time due to metabolism and distribution in the body before the molecule acts on its target and that the patient feels the benefits.
- the third difficulty results from the consequences that such a massive diffusion of the active molecule can cause in the body, consequences which result in known side effects.
- Non-steroidal anti-inflammatory drugs such as ibuprofen have been widely used for years to treat acute pain. They act on the mediators of inflammation, namely tissue enzymes including cyclooxygenases 1 and 2 and prostaglandins.
- Ibuprofen or 2- (4- (2-methylpropyl) phenyl) propanoic acid, has long been used as an analgesic for inflammation.
- Ibuprofen has multiple actions on different inflammatory pathways and cellular systems involved in acute and chronic inflammation. The main pharmacodynamic actions of ibuprofen, like those of other non-steroidal anti-inflammatory drugs, are the implications for the control of acute pain, fever and acute inflammatory reactions.
- Ibuprofen can be given in the form of high dose tablets, 200 and 400 mg
- Another non-steroidal anti-inflammatory drug, flurbiprofen has already been described in this indication, (WO 2006/092569).
- the shorter half-life of ibuprofen, about 2 hours compared to 4 hours of flurbiprofen, is beneficial for local treatment, as it allows for more doses during the day and therefore more opportunities for patient relief. and therefore a better adaptation of the dosage to the demand.
- sucking tablet For local treatment, two dosage forms seem adequate, the sucking tablet and the drug lozenges. It is found in several patent applications the tablet to be sucked, for example based on ibuprofen lysinate (FR 2865648).
- these sucking tablets can cause problems. Indeed they can be swallowed before being completely dissolved and then we find the problems related to the ingestion of drugs (choking, suffocation by obstruction of the throat). Moreover, these disadvantages can be at the origin of the cessation of treatment. These problems concern in particular elderly people and children. The choice of the pharmaceutical form was therefore focused on the pellet.
- Medicated sucking lozenges also called cooked sugars, are preparations based on sweetening substances, of solid consistency, intended to dissolve in the oral cavity. Their shape can be varied, spherical, cylindrical, square, rectangular or polygonal. They are prepared from a syrup of sweet diluent substance boiled, then baked at a higher temperature, typically from 100 ° C to 160 ° C. To this sweet base are added auxiliary substances such as sweeteners, antioxidants, dyes, flavors, and the active ingredient (s). It is during the cooking or during the cooling that the active ingredient (s) are added to the mass in a mixer as well as the auxiliary substances. The mass thus prepared is kneaded on a cold and suitable surface, then rolled and spun, then pressed and cut into pellets in shape and size. desired.
- a matrix agent may be added to the composition in order to slow the release of the active ingredient (s).
- the dissolution time in the oral cavity of the pellet is then at least 15 minutes.
- the matrix agent gives the pellet increased resistance, durable even in contact with saliva so that the patient can not bite this pellet and swallow pieces.
- the matrix agent is chosen from the group consisting of non-cellulosic polysaccharides, cellulose derivatives, acrylic acid polymers, fatty substances, polyvinylpyrrolidone, these substances being used alone or as a mixture and representing 1 to 10% by weight. weight of the pellet.
- the matrix agent is selected from the group consisting of: guar gum, locust bean gum, sodium and potassium alginate, agar-agar, carragaheen, gum arabic, gum sterculia , gum tragacanth.
- the matrix agent is selected from the group consisting of: hydroxypropylcellulose,
- Hydroxypropyl methylcellulose hydroxyethylcellulose, ethyl cellulose.
- the acrylic acid polymer is a carbomer or a polymethacrylate, a copolymer of vinyl acetate.
- the fatty substance is selected from the group consisting of waxes, gelucires, glyceryl behenate, glyceryl palmitostearate.
- the medicinal pellets of cooked sugar are composed in high proportion of a sweet diluent substance or excipient forming the base of the preparation, which can be: sucrose, fructose, lactose, maltose, sorbitol, mannitol, lactitol , glucose, maltitol, isomalt, polydextrose, maltodextrins, used alone or as a mixture and represents 80 to 99% by weight of the pellet.
- a sweet diluent substance or excipient forming the base of the preparation, which can be: sucrose, fructose, lactose, maltose, sorbitol, mannitol, lactitol , glucose, maltitol, isomalt, polydextrose, maltodextrins, used alone or as a mixture and represents 80 to 99% by weight of the pellet.
- the tablet further comprises at least one auxiliary substance chosen from sweeteners, antioxidants, dyes and flavors.
- One or more sweeteners may be selected from the group consisting of: acesulfame, aspartame, cyclamic acid and its salts, isomalt, saccharin and its salts, sucralose, alitame, thaumatin, glycyrrhizic acid and its salts, neohesperidin dihydrochalcone, steviol glucosides, neotame, aspartame-acesulfame salt, tagatose, polyglycitol syrup, maltitol, maltitol syrup, lactitol, xylitol, 1 erythritol.
- One or more antioxidants may be selected from the group consisting of: ascorbic acid, sodium ascorbate, calcium ascorbate, ascorbyl diacetate, ascorbyl palmitate, ascorbyl stearate, various tocopherols, gallates, guaiac resin, erythorbic acid, sodium erythorbate, potassium or calcium isoascorbate, butylhydroquinone, butylhydroxyanisol, butylhydroxytoluene.
- the dyes and flavors may be natural and / or artificial, they are well known to those skilled in the art.
- the method of manufacturing medicinal pellets comprises four steps, a boiling step, a cooking step, a mixing step and a step of making the cooked sugar lozenges.
- the manufacturing process is in line with current pharmaceutical requirements.
- the pellet dosage form is very specific, having been the subject of a monograph in the French Pharmacopoeia.
- Pellets are solid-consistency saccharoids intended to slowly disintegrate in the oral cavity. They are especially in a hemispherical form and generally weigh between 1 g and 3 g.
- oral-pharyngeal affection in the sense of the present invention all sore throat, in particular acute sore throat, the causes being viral in the vast majority of cases, ie the pharyngeal pain caused by a inflammation located in the oral cavity, larynx and / or pharynx. Redness of the throat associated with difficulty swallowing are classic manifestations of sore throat. It should also include angina, ie inflammation of the pharynx and tonsils, rhinopharyngitis which is an inflammation of the upper floor of the pharynx, allergies such as rhinitis can cause itching of the palate, laryngitis, inflammation Acute larynx but also stomatitis, canker sores and gingivitis.
- the present invention provides novel medicinal pellets of cooked sugar, of solid consistency based on ibuprofen. They make it possible to locally treat pathologies of the oral sphere and to release the active ingredient on the surface of the oropharyngeal zone to be treated while being less dosed than current pharmaceutical forms.
- WO2006 / 092569 discloses cooked sugar sucking drug lozenges comprising a nonsteroidal anti-inflammatory drug, mainly flurbiprofen for use in treating sore throat.
- the disclosed invention relates to a novel process for producing a pharmaceutical tablet formulation including a step of obtaining a liquid composition comprising a salt of a nonsteroidal anti-inflammatory drug. Examples of the preparation of liquid compositions are reported in the patent application. Numerous liquid compositions comprising flurbiprofen are thus described, some examples comprising ibuprofen in the form of sodium salt or potassium salt are also mentioned. However, the stability studies of these liquid compositions mention only flurbiprofen.
- the present invention is to use a salt of ibuprofen to better withstand the temperature increase.
- Three salts are likely to be used by this process, arginine, lysinate and sodium dihydrate.
- the present invention therefore relates to drug pellets sucking cooked sugar, solid consistency, for dissolving in the oral cavity, comprising as active ingredient ibuprofen sodium dihydrate (CAS No. 31121-93-4).
- the dose of ibuprofen per tablet is between 5 and 50 mg (ie between 6.4 and 64 mg of ibuprofen sodium dihydrate).
- the dose of ibuprofen per tablet is 15 mg (equivalent to 19.2 mg of ibuprofen sodium dihydrate).
- the dose of ibuprofen per tablet is 25 mg (equivalent to 32 mg of ibuprofen sodium dihydrate).
- the dose of ibuprofen per tablet is 35 mg (equivalent to 44.8 mg of ibuprofen sodium dihydrate).
- the medicinal pellet based on ibuprofen sodium dihydrate is intended for adults or children over 12 years.
- the ibuprofen sodium dihydrate pellet is intended for children over 6 years of age. Indeed, a safety pharmacology profile has been established in children and this pharmaceutical form, that is to say the drug pellet of cooked sugar can be used in children over 6 years.
- the medicinal pellet based on ibuprofen sodium dihydrate additionally comprises at least one other active principle that is useful in oral-pharyngeal conditions.
- an analgesic a non-steroidal anti-inflammatory, a local anesthetic, an antiseptic, a local antibacterial, a corticosteroid for local use.
- the present invention also relates to the use of ibuprofen sodium dihydrate drug pellet for the manufacture of a medicament for the treatment of oral and pharyngeal conditions.
- ibuprofen The stability study of ibuprofen was performed on 2.5g pellets containing ibuprofen salts of arginine, sodium or lysinate. Different storage conditions were tested, temperature, 25 or 40 ° C, relative humidity (RH) 60 or 75%, these tests were performed at T0, at 15 days, at 1, 2 and 3 months.
- RH relative humidity
- 40 75 0 3.86 0.40 3.10 represents the base time, T15 j: to 15 days
- T ° C temperature
- RH relative humidity
- Co pi packaging of the pill box
- F closed pillbox
- 0 open pill box
- the underlined values represent the significant presence of impurities greater than 0.25% with respect to the initial content.
- composition having the lowest impurity level regardless of the temperature and humidity conditions over time is the sodium salt dihydrate (Table 1).
- the form that degrades the least under conditions of temperature and specific humidity is the sodium salt dihydrate with a percentage of impurities that does not vary significantly unlike the arginine and lysinate salts.
- Example 2 Pellet composition according to the invention
- Example 3 Pellet composition according to the invention
- the main objective is to compare the effect of the pellets according to the invention dosed at 25 mg ibuprofen compared to placebo on the total relief of pain over a period of 2 hours after the first administration of the product.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2015006011A MX2015006011A (es) | 2012-11-14 | 2013-11-14 | Pastilla medicinal a base de ibuprofeno sodico dihidratado. |
CN201380059202.7A CN104780907A (zh) | 2012-11-14 | 2013-11-14 | 基于布洛芬钠二水合物的药用含片 |
AU2013346775A AU2013346775B2 (en) | 2012-11-14 | 2013-11-14 | Medicinal lozenge based on ibuprofen sodium dihydrate |
AP2015008515A AP2015008515A0 (en) | 2012-11-14 | 2013-11-14 | Medicinal lozenge based on ibuprofen sodium dihydrate |
MA38162A MA38162B1 (fr) | 2012-11-14 | 2013-11-14 | Pastille medicamenteuse a base d'ibuprofene sodique dihydrate |
BR112015010808A BR112015010808A2 (pt) | 2012-11-14 | 2013-11-14 | pastilha medicamentosa à base de ibuprofeno sódico di-hidratado |
EP13789817.7A EP2919752A1 (fr) | 2012-11-14 | 2013-11-14 | Pastille medicamenteuse a base d'ibuprofene sodique dihydrate |
US14/442,607 US20160287514A1 (en) | 2012-11-14 | 2013-11-14 | Medicinal lozenge based on ibuprofen sodium dihydrate |
CA2890832A CA2890832A1 (fr) | 2012-11-14 | 2013-11-14 | Pastille medicamenteuse a base d'ibuprofene sodique dihydrate |
JP2015542267A JP6258342B2 (ja) | 2012-11-14 | 2013-11-14 | イブプロフェンナトリウム二水和物に基づく薬用トローチ |
RU2015122217A RU2015122217A (ru) | 2012-11-14 | 2013-11-14 | Медицинские пастилки на основе дигидрата ибупрофена натрия |
TNP2015000176A TN2015000176A1 (fr) | 2012-11-14 | 2015-05-07 | Pastille medicamenteuse a base d'ibuprofene sodique dihydrate |
ZA2015/04280A ZA201504280B (en) | 2012-11-14 | 2015-06-12 | Medicinal lozenge based on ibuprofen sodium dihydrate |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1260815 | 2012-11-14 | ||
FR1260815A FR2997856B1 (fr) | 2012-11-14 | 2012-11-14 | Pastille medicamenteuse a base d'ibuprofene sodique dihydrate |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014076203A1 true WO2014076203A1 (fr) | 2014-05-22 |
Family
ID=48050846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2013/073868 WO2014076203A1 (fr) | 2012-11-14 | 2013-11-14 | Pastille medicamenteuse a base d'ibuprofene sodique dihydrate |
Country Status (17)
Country | Link |
---|---|
US (1) | US20160287514A1 (fr) |
EP (1) | EP2919752A1 (fr) |
JP (1) | JP6258342B2 (fr) |
KR (1) | KR20150084919A (fr) |
CN (1) | CN104780907A (fr) |
AP (1) | AP2015008515A0 (fr) |
AU (1) | AU2013346775B2 (fr) |
BR (1) | BR112015010808A2 (fr) |
CA (1) | CA2890832A1 (fr) |
CL (1) | CL2015001308A1 (fr) |
FR (1) | FR2997856B1 (fr) |
MA (1) | MA38162B1 (fr) |
MX (1) | MX2015006011A (fr) |
RU (1) | RU2015122217A (fr) |
TN (1) | TN2015000176A1 (fr) |
WO (1) | WO2014076203A1 (fr) |
ZA (1) | ZA201504280B (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7214331B2 (ja) * | 2016-12-28 | 2023-01-30 | 小林製薬株式会社 | 医薬組成物 |
WO2019104050A1 (fr) * | 2017-11-27 | 2019-05-31 | Lodaat Pharmaceuticals | Procédés de préparation de compositions curcuminoïdes |
KR20220050932A (ko) * | 2019-08-22 | 2022-04-25 | 어플라이드 바이올로지컬 래버러토리즈 인코포레이티드 | 비-스테로이드성 항-염증 약물을 사용한 조성물 및 방법 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2865648A1 (fr) | 2004-02-03 | 2005-08-05 | Philippe Perovitch | Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede |
WO2005120459A2 (fr) * | 2004-06-07 | 2005-12-22 | Strides Arcolab Limited | Composition pharmaceutique renfermant une solution stable et claire de medicament anti-inflammatoire contenue dans une capsule gelatineuse molle, et procede de production correspondant |
WO2006092569A1 (fr) | 2005-03-01 | 2006-09-08 | Reckitt Benckiser Healthcare (Uk) Limited | Procédé de fabrication de losanges contenant un nsaid, leurs compositions, leur utilisation médicinale |
WO2007055887A1 (fr) * | 2005-11-02 | 2007-05-18 | Teikoku Pharma Usa, Inc. | Formulations de doses orales d'ibuprofene organoleptiquement acceptables, procedes de preparation et d'utilisation de celles-ci |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2145219C1 (ru) * | 1991-05-13 | 2000-02-10 | Дзе Бутс Компани ПЛС | Фармацевтическая композиция, содержащая s(-)-2-(4-изобутилфенил)пропионат натрия, способ получения натриевой соли энантиомера 2-(4-изобутилфенил)пропионовой кислоты, s(-)-2-(4-изобутилфенил)пропионат натрия дигидрат |
GB9710521D0 (en) * | 1997-05-22 | 1997-07-16 | Boots Co Plc | Process |
CH693586A8 (de) * | 2002-10-14 | 2003-12-15 | Roche Consumer Health Ag | Darreichungsform von Ibuprofen-Natrium. |
AU2005271036B2 (en) * | 2004-08-12 | 2009-11-19 | Reckitt Benckiser Healthcare (Uk) Limited | Granules comprising paracetamol a NSAID and a sugar alcohol made by melt extrusion |
JP2009538359A (ja) * | 2006-05-26 | 2009-11-05 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 置換カルボン酸化合物の製造および利用 |
CN102557918B (zh) * | 2011-11-28 | 2013-08-21 | 海南永田药物研究院有限公司 | 一种布洛芬钠化合物及其制法 |
-
2012
- 2012-11-14 FR FR1260815A patent/FR2997856B1/fr not_active Expired - Fee Related
-
2013
- 2013-11-14 MX MX2015006011A patent/MX2015006011A/es unknown
- 2013-11-14 BR BR112015010808A patent/BR112015010808A2/pt not_active Application Discontinuation
- 2013-11-14 US US14/442,607 patent/US20160287514A1/en not_active Abandoned
- 2013-11-14 AU AU2013346775A patent/AU2013346775B2/en not_active Ceased
- 2013-11-14 RU RU2015122217A patent/RU2015122217A/ru not_active Application Discontinuation
- 2013-11-14 EP EP13789817.7A patent/EP2919752A1/fr not_active Ceased
- 2013-11-14 WO PCT/EP2013/073868 patent/WO2014076203A1/fr active Application Filing
- 2013-11-14 CA CA2890832A patent/CA2890832A1/fr not_active Abandoned
- 2013-11-14 JP JP2015542267A patent/JP6258342B2/ja not_active Expired - Fee Related
- 2013-11-14 KR KR1020157015135A patent/KR20150084919A/ko not_active Application Discontinuation
- 2013-11-14 MA MA38162A patent/MA38162B1/fr unknown
- 2013-11-14 AP AP2015008515A patent/AP2015008515A0/xx unknown
- 2013-11-14 CN CN201380059202.7A patent/CN104780907A/zh active Pending
-
2015
- 2015-05-07 TN TNP2015000176A patent/TN2015000176A1/fr unknown
- 2015-05-14 CL CL2015001308A patent/CL2015001308A1/es unknown
- 2015-06-12 ZA ZA2015/04280A patent/ZA201504280B/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2865648A1 (fr) | 2004-02-03 | 2005-08-05 | Philippe Perovitch | Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede |
WO2005120459A2 (fr) * | 2004-06-07 | 2005-12-22 | Strides Arcolab Limited | Composition pharmaceutique renfermant une solution stable et claire de medicament anti-inflammatoire contenue dans une capsule gelatineuse molle, et procede de production correspondant |
WO2006092569A1 (fr) | 2005-03-01 | 2006-09-08 | Reckitt Benckiser Healthcare (Uk) Limited | Procédé de fabrication de losanges contenant un nsaid, leurs compositions, leur utilisation médicinale |
WO2007055887A1 (fr) * | 2005-11-02 | 2007-05-18 | Teikoku Pharma Usa, Inc. | Formulations de doses orales d'ibuprofene organoleptiquement acceptables, procedes de preparation et d'utilisation de celles-ci |
Non-Patent Citations (6)
Title |
---|
CENSI ET AL., J. THERM ANAL CALORIM, vol. 111, 2013, pages 2009 - 2018 |
FRYE ET AL., J. FAM. PRACT., vol. 60, 2011, pages 293 - 294 |
PIERRE FABRE MEDICAMENT: "Analgesic profile of 3 new Ibuprofen lozenges after single administration in acute sore throat pain", INTERNATIONAL CLINICAL TRIALS REGISTRY PLATFORM, 17 December 2012 (2012-12-17), pages 1 - 4, XP055069266, Retrieved from the Internet <URL:http://apps.who.int/trialsearch/trial.aspx?trialid=EUCTR2011-005848-10-DE> [retrieved on 20130702] * |
SCHACHTEL ET AL., CLI. PHARMACOL. THER., vol. 55, 1994, pages 464 - 470 |
See also references of EP2919752A1 |
WILSON M L ET AL: "Development of an ibuprofen lozenge for the elderly", DRUGS MADE IN GERMANY, EDITIO CANTOR VERLAG, DE, vol. 38, no. 3, 1 January 1995 (1995-01-01), pages 90 - 95, XP009170725, ISSN: 0012-6683 * |
Also Published As
Publication number | Publication date |
---|---|
EP2919752A1 (fr) | 2015-09-23 |
US20160287514A1 (en) | 2016-10-06 |
AP2015008515A0 (en) | 2015-06-30 |
CA2890832A1 (fr) | 2014-05-22 |
MA38162A1 (fr) | 2016-12-30 |
BR112015010808A2 (pt) | 2017-07-11 |
JP2015537019A (ja) | 2015-12-24 |
TN2015000176A1 (fr) | 2016-10-03 |
ZA201504280B (en) | 2017-09-27 |
AU2013346775B2 (en) | 2018-06-28 |
JP6258342B2 (ja) | 2018-01-10 |
CN104780907A (zh) | 2015-07-15 |
CL2015001308A1 (es) | 2015-08-28 |
RU2015122217A (ru) | 2017-01-10 |
MX2015006011A (es) | 2015-09-10 |
KR20150084919A (ko) | 2015-07-22 |
FR2997856B1 (fr) | 2015-04-24 |
MA38162B1 (fr) | 2019-12-31 |
FR2997856A1 (fr) | 2014-05-16 |
AU2013346775A1 (en) | 2015-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017200329B2 (en) | Sublingual apomorphine | |
JP5213446B2 (ja) | ジクロフェナクを含む医薬組成物 | |
CA2838589C (fr) | Forme pharmaceutique orale comestible de type bande ou cachet contenant une resine echangeuse d'ions pour le masquage du gout | |
KR20180094143A (ko) | 설하 필름 | |
PT1998762E (pt) | Forma farmacêutica sólida contendo um agente activo de sabor mascarado | |
EP1711162B1 (fr) | Composition pour l'utilisation dans le traitement local des affections bucco-pharyngées comprenant de l'ibuprofène ou du kétoprofène | |
WO2014076203A1 (fr) | Pastille medicamenteuse a base d'ibuprofene sodique dihydrate | |
FR2649611A1 (fr) | Procede de preparation galenique d'une composition therapeutique notamment a base d'aspirine | |
TW201347753A (zh) | 包含甲基丙烯酸共聚物之布洛芬(ibuprofen)固體口服劑型組成物 | |
JP2012031164A (ja) | フィルム状製剤 | |
TR2023019306A2 (tr) | Kerseti̇n, hi̇bi̇skus ekstresi̇, stevi̇a ve kafei̇n'i̇ bi̇r arada i̇çeren sporcular i̇çi̇n performans artirici oral i̇nce fi̇lm formülasyonlari | |
WO2022201090A1 (fr) | Composition de film à désintégration orale de kétorolac et son procédé de préparation | |
TR2023019879A2 (tr) | Kolşi̇si̇n i̇le febuksostat nanokri̇stalleri̇ni̇ bi̇r arada i̇çeren oral i̇nce fi̇lm formülasyonlari |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13789817 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2890832 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2015542267 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14442607 Country of ref document: US Ref document number: MX/A/2015/006011 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015010808 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20157015135 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 38162 Country of ref document: MA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15134636 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013789817 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015122217 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2013346775 Country of ref document: AU Date of ref document: 20131114 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112015010808 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150512 |